prednisone has been researched along with Hypokalemia in 23 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Hypokalemia: Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective is to report the clinical case of a patient with castration-resistant metastatic prostate cancer who developed ascending flaccid paralysis secondary to severe hypokalemia, probably due to hyperaldosteronism secondary to the use of Abiraterone Acetate, despite the use of Prednisone." | 8.31 | Ascending Flaccid Paralysis Secondary to Hypokalemia in A Cancer Patient using Abiraterone - A Case Report. ( Cintra, MTG; Costa, AL; de Almeida, DCB; de Carvalho, FB; de Oliveira Faria, BL, 2023) |
| "To investigate the correlation between decrease of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) activity and hypokalemia induced by furosemide (Fur) in rats." | 7.71 | Correlation between decrease of 11beta-hydroxysteroid dehydrogenase activity and hypokalemia induced by furosemide in rats. ( Shen, JP; Yao, B; Zhang, YD, 2001) |
| "While abiraterone acetate (AA) has demonstrated survival benefit in advanced prostate cancer (APC), meaningful cardiotoxicity is observed." | 5.41 | Association between RCT methodology and disease indication with mineralocorticoid-related toxicity for patients receiving abiraterone acetate for advanced prostate cancer: A meta-analysis of RCTs. ( Hall, ME; Klaassen, Z; Laviana, AA; Luckenbaugh, AN; Magee, DE; Padgett, WJ; Satkunasivam, R; Schaffer, K; Wallis, CJD, 2023) |
| "The objective is to report the clinical case of a patient with castration-resistant metastatic prostate cancer who developed ascending flaccid paralysis secondary to severe hypokalemia, probably due to hyperaldosteronism secondary to the use of Abiraterone Acetate, despite the use of Prednisone." | 4.31 | Ascending Flaccid Paralysis Secondary to Hypokalemia in A Cancer Patient using Abiraterone - A Case Report. ( Cintra, MTG; Costa, AL; de Almeida, DCB; de Carvalho, FB; de Oliveira Faria, BL, 2023) |
| "To investigate the correlation between decrease of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) activity and hypokalemia induced by furosemide (Fur) in rats." | 3.71 | Correlation between decrease of 11beta-hydroxysteroid dehydrogenase activity and hypokalemia induced by furosemide in rats. ( Shen, JP; Yao, B; Zhang, YD, 2001) |
| " A 64-year-old woman with diffuse histiocytic lymphoma developed persistent hypokalemia following a course of Cytoxan (cyclophosphamide), Adriamycin (doxorubicin), vincristine, and prednisone (CHOP)-Bleo." | 3.67 | Potassium-wasting nephropathy secondary to chemotherapy simulating Bartter's syndrome. ( Floyd, M; Lieber, IH; McGuffin, WL; Stoneburner, SD, 1984) |
| " Grade 3/4 adverse events occurred in 62% of elderly patients and in 60% of patients aged <75 yr treated with AA plus P." | 2.79 | Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. ( Chi, KN; Fizazi, K; Haqq, CM; Higano, CS; Kheoh, T; Li, J; Marberger, M; Molina, A; Mulders, PF; Saad, F, 2014) |
| "Two patients with chronic sialoadenitis had features of Bartter's and Gitelman's syndrome, respectively." | 1.30 | Hypokalaemic alkalosis, acquired Gitelman's and Bartter's syndrome in chronic sialoadenitis. ( Bartoli, E; Casatta, L; Ferraccioli, GF, 1997) |
| "Changes in beta 2-adrenoceptor function by chronic dosing of beta 2-mimetics and the possible influence of a single dose of prednisone have been studied as changes over time in the concentration-effect relationship of the beta 2-adrenoceptor agonist terbutaline." | 1.29 | Pharmacodynamic modelling of the drug-induced downregulation of a beta 2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone. ( Braat, MC; Jonkers, RE; Koopmans, RP; van Boxtel, CJ, 1995) |
| "The patient had histamine-fast achlorhydria and a normal gastric biopsy and no gastrin was recovered from the tumour tissue." | 1.24 | WATERY DIARRHOEA AND AN ISLET CELL TUMOUR. ( CREAMER, B; HINDLE, W; MCBRIEN, DJ, 1964) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (52.17) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 2 (8.70) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| de Almeida, DCB | 1 |
| Costa, AL | 1 |
| de Oliveira Faria, BL | 1 |
| de Carvalho, FB | 1 |
| Cintra, MTG | 1 |
| Hall, ME | 1 |
| Padgett, WJ | 1 |
| Klaassen, Z | 1 |
| Magee, DE | 1 |
| Luckenbaugh, AN | 1 |
| Laviana, AA | 1 |
| Satkunasivam, R | 1 |
| Schaffer, K | 1 |
| Wallis, CJD | 1 |
| Calvani, J | 1 |
| Elia, R | 1 |
| Battistella, M | 1 |
| Delyon, J | 1 |
| Vivier-Chicoteau, J | 1 |
| Gornet, JM | 1 |
| Lebbé, C | 1 |
| Baroudjian, B | 1 |
| Bertheau, P | 1 |
| Mulders, PF | 1 |
| Molina, A | 1 |
| Marberger, M | 1 |
| Saad, F | 1 |
| Higano, CS | 1 |
| Chi, KN | 1 |
| Li, J | 1 |
| Kheoh, T | 1 |
| Haqq, CM | 1 |
| Fizazi, K | 1 |
| Polanco, NA | 1 |
| Soto-Abraham, MV | 1 |
| Rodríguez-Castellanos, FE | 1 |
| Liu, AY | 1 |
| Lowe, RC | 1 |
| Levy, BD | 1 |
| Katz, JT | 1 |
| Loscalzo, J | 1 |
| Rastegar, A | 1 |
| CONTE, M | 1 |
| FOUET, P | 1 |
| JACOBS, C | 1 |
| HINDLE, W | 1 |
| MCBRIEN, DJ | 1 |
| CREAMER, B | 1 |
| DE GRAEFF, J | 1 |
| LAMEIJER, LD | 1 |
| Jhamb, R | 1 |
| Gupta, N | 1 |
| Garg, S | 1 |
| Kumar, S | 1 |
| Gulati, S | 1 |
| Mishra, D | 1 |
| Beniwal, P | 1 |
| Lieber, IH | 1 |
| Stoneburner, SD | 1 |
| Floyd, M | 1 |
| McGuffin, WL | 1 |
| Read, NW | 1 |
| Read, MG | 1 |
| Krejs, GJ | 1 |
| Hendler, RS | 1 |
| Davis, G | 1 |
| Fordtran, JS | 1 |
| Jonkers, RE | 1 |
| Braat, MC | 1 |
| Koopmans, RP | 1 |
| van Boxtel, CJ | 1 |
| Casatta, L | 1 |
| Ferraccioli, GF | 1 |
| Bartoli, E | 1 |
| Yao, B | 1 |
| Zhang, YD | 1 |
| Shen, JP | 1 |
| Jerusalem, F | 1 |
| Knappe, G | 1 |
| Flemming, F | 1 |
| Stobbe, H | 1 |
| Wendt, F | 1 |
| Marks, IN | 1 |
| Bank, S | 1 |
| Louw, JH | 1 |
| Schaison, G | 1 |
| Powell, JR | 1 |
| Walther, H | 1 |
| Gajdos, A | 1 |
| Weil, J | 1 |
| Gajdos-Török, M | 1 |
| Coupry, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy[NCT00638690] | Phase 3 | 1,195 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A prostate-specific antigen (PSA) response was defined as a >=50% decline from baseline. (NCT00638690)
Timeframe: Up to 12 months
| Intervention | Participants (Number) |
|---|---|
| Abiraterone Acetate | 232 |
| Placebo | 22 |
Overall survival is defined as the time interval from the date of randomization to the date of death from any cause. (NCT00638690)
Timeframe: Up to 60 months
| Intervention | Days (Median) |
|---|---|
| Abiraterone Acetate | 450.0 |
| Placebo | 332.0 |
Radiographic progression-free survival is based on imaging studies according to modified Response Evaluation Criteria in Solid Tumors (RECIST): baseline lymph node size must be >=2.0 cm to be considered a target lesion; progression on bone scans with >=2 new lesions not consistent with tumor flare, confirmed on a second scan >=6 weeks later that shows >=1 additional new lesion. (NCT00638690)
Timeframe: Up to 11 months
| Intervention | Days (Median) |
|---|---|
| Abiraterone Acetate | 171.0 |
| Placebo | 110.0 |
The time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the protocol-specific Prostate Specific Antigen Working Group (PSAWG) criteria, namely, a PSA level of at least 5 ng/ml that has risen on at least 2 successive occasions, at least 2 weeks apart. (NCT00638690)
Timeframe: Up to 12 months
| Intervention | Days (Median) |
|---|---|
| Abiraterone Acetate | 309.0 |
| Placebo | 200.0 |
2 reviews available for prednisone and Hypokalemia
| Article | Year |
|---|---|
Association between RCT methodology and disease indication with mineralocorticoid-related toxicity for patients receiving abiraterone acetate for advanced prostate cancer: A meta-analysis of RCTs.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Humans; Hyperte | 2023 |
[Treatment of myopathies and spinal muscular atrophies (author's transl)].
Topics: Amyotrophic Lateral Sclerosis; Azathioprine; Collagen Diseases; Dermatomyositis; Glycogen Storage Di | 1978 |
1 trial available for prednisone and Hypokalemia
| Article | Year |
|---|---|
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Com | 2014 |
20 other studies available for prednisone and Hypokalemia
| Article | Year |
|---|---|
Ascending Flaccid Paralysis Secondary to Hypokalemia in A Cancer Patient using Abiraterone - A Case Report.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Hypokalemia; Male; Para | 2023 |
[An unusual digestive complication under anti-PD-1 (pembrolizumab)].
Topics: Aged; Antibodies, Monoclonal, Humanized; Budesonide; Colitis, Collagenous; Diarrhea; Humans; Hypokal | 2020 |
Nephrocalcinosis and distal renal tubular acidosis in Sjögren's syndrome.
Topics: Acidosis, Renal Tubular; Adult; Delayed Diagnosis; Humans; Hypercalciuria; Hypokalemia; Male; Nephri | 2013 |
Clinical problem-solving. A rash hypothesis.
Topics: Adult; Biopsy; Blood Cell Count; Bone Marrow; Colon; Diagnosis, Differential; Diarrhea; Drug Therapy | 2010 |
Attending rounds: patient with hypokalemia and metabolic acidosis.
Topics: Acidosis; Acidosis, Renal Tubular; Adult; Bicarbonates; Female; Humans; Hypokalemia; Paralysis; Pota | 2011 |
[WATER RETENTION IN CIRRHOTICS. PHYSIOPATHOLOGICAL DATA AND THERAPEUTIC RESULTS].
Topics: Ascites; Edema; Heart Failure; Humans; Hypokalemia; Hyponatremia; Liver Cirrhosis; Mineralocorticoid | 1963 |
WATERY DIARRHOEA AND AN ISLET CELL TUMOUR.
Topics: Achlorhydria; Adenoma, Islet Cell; Aldosterone; Cortisone; Dexamethasone; Diarrhea; Feces; Gastrins; | 1964 |
PERIODIC PARALYSIS.
Topics: Adolescent; Chlorides; Cortisone; Diet Therapy; Diet, Sodium-Restricted; Digoxin; Drug Therapy; Gene | 1965 |
Diffuse lymphomatous infiltration of kidney presenting as renal tubular acidosis and hypokalemic paralysis: case report.
Topics: Acid-Base Equilibrium; Acidosis, Renal Tubular; Adult; Antigens, CD19; Antigens, CD20; Antineoplasti | 2007 |
Potassium-wasting nephropathy secondary to chemotherapy simulating Bartter's syndrome.
Topics: Aldosterone; Antineoplastic Combined Chemotherapy Protocols; Bartter Syndrome; Bleomycin; Cyclophosp | 1984 |
A report of five patients with large-volume secretory diarrhea but no evidence of endocrine tumor or laxative abuse.
Topics: Adult; Aged; Cathartics; Chronic Disease; Colon; Diarrhea; Electrolytes; Endocrine System Diseases; | 1982 |
Pharmacodynamic modelling of the drug-induced downregulation of a beta 2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone.
Topics: Adrenergic beta-Agonists; Adult; Down-Regulation; Female; Glucocorticoids; Humans; Hypokalemia; Male | 1995 |
Hypokalaemic alkalosis, acquired Gitelman's and Bartter's syndrome in chronic sialoadenitis.
Topics: Adult; Aged; Alkalosis; Allopurinol; Anti-Inflammatory Agents; Antimetabolites; Bartter Syndrome; Ca | 1997 |
Correlation between decrease of 11beta-hydroxysteroid dehydrogenase activity and hypokalemia induced by furosemide in rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Cortisone; Diuretics; Furosemide; Hydroxystero | 2001 |
[Pancreatic islet cell adenoma with the triad diarrhea, hypokalemia and hyperglycemia].
Topics: Adenoma, Islet Cell; Adult; Diarrhea; Female; Humans; Hyperglycemia; Hypokalemia; Prednisone; Radiog | 1966 |
Islet cell tumor of the pancreas with reversible watery diarrhea and achylorhydraia.
Topics: Achlorhydria; Adenoma, Islet Cell; Adult; Diarrhea; Gastric Acidity Determination; Gastric Juice; Hu | 1967 |
[The practitioner's approach to acute hypercalcemia].
Topics: Acute Disease; Animals; Bone Neoplasms; Calcitonin; Diet Therapy; Edetic Acid; Humans; Hypercalcemia | 1969 |
Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application.
Topics: Absorption; Aged; Colitis, Ulcerative; Electrocardiography; Female; Humans; Hydrocortisone; Hypokale | 1969 |
[Hypercalcemia syndrome in bronchial carcinoma without skeletal metastasizing].
Topics: Bronchial Neoplasms; Carcinoma, Squamous Cell; Cardiac Glycosides; Female; Humans; Hypercalcemia; Hy | 1970 |
[A new variety of porphyria, mixed or variegate hereditary coproporphyria].
Topics: Adenine Nucleotides; Child; Dehydration; Feces; Female; Humans; Hypertrichosis; Hypokalemia; Hyponat | 1969 |